Search

Your search keyword '"Lakhwani, Sunil"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Lakhwani, Sunil" Remove constraint Author: "Lakhwani, Sunil" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
32 results on '"Lakhwani, Sunil"'

Search Results

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

2. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

3. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia

4. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

5. PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.

6. PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.

7. PB2210: COMPARISON OF THREE PROGNOSTIC SCORING SYSTEMS FOR THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: ANALYSIS OF 190 PATIENTS AT THE UNIVERSITY HOSPITAL OF THE CANARY ISLANDS (1990-2022)

8. PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA

9. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

10. Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

11. Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line

12. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

13. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

14. Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

15. Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

17. Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

18. Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

21. Valor pronóstico de la recuperación de la inmunoparesia en el mieloma múltiple

23. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

24. A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

25. Outbreak of vancomycin-resistant enterococcuson a haematology ward: management and control

26. Factor neurotrófico derivado del cerebro y primeros episodios psicóticos. Estudio pronóstico de un año.

27. Cytomegalovirus-associated hemophagocytic syndrome in a patient with Crohn's disease receiving azathioprine.

29. Valor pronóstico de la amplitud de distribución eritrocitaria al diagnóstico en el linfoma difuso de células grandes B

30. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).

31. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Catalog

Books, media, physical & digital resources